Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Peptide therapy provides a minimally invasive alternative that works fast
PMID: 39921384
Why this trial matters : First oral SERD to succeed in Phase III in early breast cancer Signals a potential new adjuvant standard of care Advances endocrine therapy beyond legacy agents Johnson & Johnson Tecvayli + Darzalex Faspro Shows Unprecedented Phase III Success in Relapsed/Refractory Multiple Myeloma The Phase III MajesTEC-3 trial demonstrated that the combination of Tecvayli (teclistamab) plus Darzalex Faspro (daratumumab SC) significantly improved progression-free survival and overall survival versus standard regimens in patients with relapsed/refractory multiple myeloma as early as second-line, with an ~83% reduction in disease progression or death at almost three years follow-up
Ready to boost your energy and improve your wellness
US$ 27.01
US$ 20.53
US$ 22.23
US$ 27.13
US$ 24.32
